Skip to main content
< Back
About
About the conference
App
Organisers & Partners
Latest updates
Press room
Registration
Venue 22
About the venue
Rooms
Call for abstracts
Programme 22
Tracks 22
Speakers 22
Side events 22
Subscribe
days
hours
minutes
seconds
New psychoactive substances
Sessions
Wednesday, 23 November
10:50
Advances in toxicology
10:50
to
12:20
Central square 2 (C2)
Oral presentation session
13:20
Cannabis
13:20
to
14:50
Networking zone 2 (N2)
e-poster guided tour
15:00
Drug Early Warning Systems – the key to preparedness and response to new psychoactive substances
15:00
to
16:30
Central square 2 (C2)
Structured session
Surveillance
15:00
to
16:30
Networking zone 4 (N4)
Short communication session
16:50
Improving knowledge, protecting health
16:50
to
18:20
Networking zone 3 (N3)
Short communication session
Scanner - Understanding the dynamics and consequences of new psychoactive substances in a rapidly changing (online) drug market
16:50
to
18:20
Insights zone 4 (I4)
Structured session
Thursday, 24 November
10:50
Studying illegal drugs in socially embedded markets
10:50
to
12:20
Central square 2 (C2)
Structured session
13:20
New Psychoactive Substances
13:20
to
14:50
Insights zone 4 (I4)
Oral presentation session
Uppers, downers and psychedelics
13:20
to
14:50
Networking zone 3 (N3)
Short communication session
15:00
Insights into acute recreational drug and new psychoactive substance toxicity – an update from the Euro-DEN Plus Project
15:00
to
16:30
Central square 2 (C2)
Structured session
16:50
Unpacking the neurobiology of cannabis use disorders and cannabinoids: findings from neuroimaging and experimental studies across different ages and world regions
16:50
to
18:20
Knowledge market 2 (K2)
Structured session
Friday, 25 November
10:50
Mortality among people who use drugs
10:50
to
12:20
Knowledge market 3 (K3)
Oral presentation session
Recreational drug use and risk
10:50
to
12:20
Central square 3 (C3)
Oral presentation session
13:20
Substance use consequences and concerns
13:20
to
14:50
Networking zone 1 (N1)
e-poster guided tour
Presentations
Wednesday, 23 November
10:50
Oral presentation
Anti-doping knowledge and educational needs of Finnish pharmacists
10:50
to
12:20
Central square 2 (C2)
Jukka Koskelo
Oral presentation
The implementation of ultra-portable devices for analysis of illicit drug in drug checking service of the Canton of Vaud (Switzerland, CH)
10:50
to
12:20
Central square 2 (C2)
Emilia Gianola
Oral presentation
Characteristics of acute ecstasy-related toxicity in multiple Dutch medical settings, from 2009 through 2018
10:50
to
12:20
Central square 2 (C2)
Lonja Schurmann
Oral presentation
Metabolite profiling of synthetic cathinones: towards the identification of consumption biomarkers in forensic and clinical settings
10:50
to
12:20
Central square 2 (C2)
Alexandra Antunes
Oral presentation
Agreement between self-reported illicit drug use and biological samples: a systematic review and meta-analysis
10:50
to
12:20
Central square 2 (C2)
Chrianna Bharat
13:20
e-poster
The synthetic cannabinoid ADB-FUBINACA modulates epigenetic mechanisms during in vitro neuronal differentiation at biologically relevant concentrations
13:20
to
14:50
Networking zone 2 (N2)
Felix Carvalho
e-poster
Profiles of individuals with cannabis-related disorders
13:20
to
14:50
Networking zone 2 (N2)
Marie-Josée Fleury
e-poster
The effects of Synthetic Cannabinoids ADB-FUBINACA, AMB-FUBINACA, AB-CHMINACA and HU-308 on Differentiation and Proliferation of Brain NG108-15 Cells
13:20
to
14:50
Networking zone 2 (N2)
Carolina Freitas
e-poster
Crosstalk between autophagic intermediaries in the event of neurotoxic effects mediated by Synthetic Cannabinoids in NG108-15 cells
13:20
to
14:50
Networking zone 2 (N2)
Catarina Teixeira
e-poster
Treating cannabis use disorder in young adults with text-delivered peer network counseling: A large, multi-site, randomized clinical trial.
13:20
to
14:50
Networking zone 2 (N2)
Michael Mason
e-poster
The arrival of Edibles in Quebec cannabis market : what can be done to minimize the health impact?
13:20
to
14:50
Networking zone 2 (N2)
Julie Loslier
e-poster
What difference will 2.5 grams make? Canada responds to British Columbia’s overdose crisis by agreeing to decriminalize possession of small amounts of drugs
13:20
to
14:50
Networking zone 2 (N2)
Lori Hanson
e-poster
Prevalence and correlates of cannabis use for medicinal reasons – an Australian cross- sectional study
13:20
to
14:50
Networking zone 2 (N2)
Janni Leung
e-poster
Fifth of the inhabitants of Slovenia has already used cannabis or cannabis-derived products for health purposes or is considering it
13:20
to
14:50
Networking zone 2 (N2)
Ada Hocevar Grom
15:00
Short communication
Findings from novel methods of surveillance for fentanyl and novel psychoactive substances within Supervised Injecting Facilities
15:00
to
16:30
Networking zone 4 (N4)
Suzanne Nielsen
Short communication
Detection of Potent 'Nitazene' Synthetic Opioids by a networked drug checking service in Toronto, Ontario, Canada
15:00
to
16:30
Networking zone 4 (N4)
Kristy Scarfone
Short communication
Access to medical cannabis in Brazil: informal regulation via patient associations as a social movement
15:00
to
16:30
Networking zone 4 (N4)
Paulo J. R. Pereira
Short communication
Method development for monitoring Google-indexed e-shops offering new psychoactive substances (NPS) in The Netherlands.
15:00
to
16:30
Networking zone 4 (N4)
Lavinia Stegemann
Short communication
How to evaluate complex drug policies? A case study of the Belgian drug policy
15:00
to
16:30
Networking zone 4 (N4)
Eva Blomme
Short communication
The Unit of Cannabis: from a systematic review to a NIDA recommendation
15:00
to
16:30
Networking zone 4 (N4)
María Teresa Pons-cabrera
Short communication
A longitudinal study of a drug checking service for patrons of Boom Festival 2018: behavioral outcomes at individual and group levels.
15:00
to
16:30
Networking zone 4 (N4)
Helena Valente
Short communication
Using Reddit Social Media Data to Uncover Self-medication and Drug Use Trends among Opioid Users: Semi-automated Natural Language Processing Approach.
15:00
to
16:30
Networking zone 4 (N4)
Georgiy Bobashev
Oral presentation
5. International cooperation to address global public health harms caused by novel psychoactive substances while protecting access to medicines
15:00
to
16:30
Central square 2 (C2)
Dilkushi Poovendran
Oral presentation
1. Early warning on emerging drug threats at the international level – opportunities and challenges
15:00
to
16:30
Central square 2 (C2)
Martin Raithelhuber
Oral presentation
2. Global markets, glocal threats: Early warning, preparedness, and response to new psychoactive substances in Europe
15:00
to
16:30
Central square 2 (C2)
Michael Evans-Brown
Oral presentation
3. Early Warning Systems are Critical to Drug Control Strategies to Protect Public Health and Safety
15:00
to
16:30
Central square 2 (C2)
Luli R. Akinfiresoye,
Terrence L. Boos
Oral presentation
4. NPS Discovery: An Open Access Early Warning System for the United States
15:00
to
16:30
Central square 2 (C2)
Barry K. Logan
16:50
Oral presentation
3. Prevalence of NPS use. Results of the implementation of a standardized survey methodology amongst 25 civil society organization in Europe
16:50
to
18:20
Insights zone 4 (I4)
Jochen Schrooten
Discussion
The importance of the justice programme
16:50
to
18:20
Insights zone 4 (I4)
Koralia Kontou
Oral presentation
1. Analysis of NPS and drugs purchased on Darknet and Clearnet markets
16:50
to
18:20
Insights zone 4 (I4)
Mireia Ventura
Oral presentation
2. The influence of legislation on the availability of NPS
16:50
to
18:20
Insights zone 4 (I4)
Judith Aldridge
Short communication
Virtual Opioid User: Simulating the Effects of Counterfeit Pill Prevalence with a Control Theory Model
16:50
to
18:20
Networking zone 3 (N3)
Alexander Preiss
Short communication
The Influence of the Synthetic Cannabinoids AMB-FUBINACA, ADB-FUBINACA, AB-CHMINACA and THJ-2201 on In Vitro Viability and Senescence of SH-SY5Y Cells and Primary Rat Hippocampal Neurons
16:50
to
18:20
Networking zone 3 (N3)
Rita Roque Bravo
Short communication
Organ pathologies detected post-mortem in patients receiving opioid agonist treatment for opioid use disorder: a nationwide 2-year cross-sectional study
16:50
to
18:20
Networking zone 3 (N3)
Anne Berit Bech
Short communication
Successful microelimination of HCV among patients in the Romanian prison system
16:50
to
18:20
Networking zone 3 (N3)
Adrian Abagiu
Short communication
The synthetic cannabinoids ADB-FUBINACA and THJ-2201 decrease mitochondrial activity and ATP levels during neurodifferentiation of NG108-15 cells
16:50
to
18:20
Networking zone 3 (N3)
Rui Filipe Malheiro
Short communication
In vitro toxicity of the synthetic cannabinoids THJ-2201 and ADB-FUBINACA to human astrocytes
16:50
to
18:20
Networking zone 3 (N3)
Rafaela Silva
Short communication
Impact of the COVID-19 pandemic on drug use in the Republic of North Macedonia
16:50
to
18:20
Networking zone 3 (N3)
Sanja Prosheva
Short communication
Non-pharmacological treatment interventions in UK drug and alcohol services: an exploratory study
16:50
to
18:20
Networking zone 3 (N3)
Karen Megranahan
Introduction
Scanner - Understanding the dynamics and consequences of new psychoactive substances in a rapidly changing (online) drug market
16:50
to
18:20
Insights zone 4 (I4)
Margot Balcaen
Thursday, 24 November
10:50
Oral presentation
1. Synthetic opioids in Sweden: Analyses of public webforum discussions
10:50
to
12:20
Central square 2 (C2)
Kim Moeller
Oral presentation
2. From the jungle to the street: Country-level variation and demographic correlates of cocaine prices
10:50
to
12:20
Central square 2 (C2)
Rasmus Munksgaard
Oral presentation
3. Illegal drug markets on social media: Locally bound actors on global platforms
10:50
to
12:20
Central square 2 (C2)
Silje Anderdal Bakken
Oral presentation
4. How do you become involved in hybrid digital drug markets: Identifying explanations in a qualitative interview study with social media sellers
10:50
to
12:20
Central square 2 (C2)
Jakob Demant
13:20
Oral presentation
Codesigning an Australian National Prompt Response Network for Emerging Drugs
13:20
to
14:50
Insights zone 4 (I4)
Penelope Hill
Oral presentation
A qualitative study of people who use new psychoactive substances and harm reduction services in eight countries of Eastern Europe and Central Asia region
13:20
to
14:50
Insights zone 4 (I4)
Eliza Kurcevič
Oral presentation
In vitro pharmacological characterization of recent non-fentanyl synthetic opioids including 2-benzylbenzimidazole ‘nitazene’ opioids
13:20
to
14:50
Insights zone 4 (I4)
Marthe Vandeputte
Oral presentation
Cannabis adulterated with the synthetic cannabinoid receptor agonist MDMB-4en-PINACA and the role of European drug checking services
13:20
to
14:50
Insights zone 4 (I4)
Pieter E. Oomen
Short communication
Evaluating Cracks in the Ice – a digital health initiative to support families, health workers and communities affected by crystal methamphetamine (‘ice’)
13:20
to
14:50
Networking zone 3 (N3)
Steph Kershaw
Short communication
Exclusive therapeutic use of cannabis in France: characteristics and use patterns in a large sample of daily users
13:20
to
14:50
Networking zone 3 (N3)
Martin Bastien
Short communication
Psychoactive substance use among Serbian adults – results from online survey
13:20
to
14:50
Networking zone 3 (N3)
Biljana Kilibarda
Short communication
Harm Reduction for Chemsex in Lisbon: community-based interventions for a hard-to-reach group, during the COVID-19 pandemic
13:20
to
14:50
Networking zone 3 (N3)
Filipe Couto Gomes
Short communication
Z-Drugs Dependence: An Awakening Truth
13:20
to
14:50
Networking zone 3 (N3)
Afonso Homem De Matos
Oral presentation
The added value of drug checking data in combination with data from online drug monitoring to evaluate NPS market dynamics: the case of 3-MMC in the Netherlands.
13:20
to
14:50
Insights zone 4 (I4)
Laura Smit-rigter
Short communication
The epigenetic effects of cannabis exposure and their link to behavior and emotional manifestations – a scoping review
13:20
to
14:50
Networking zone 3 (N3)
Ana Sofia Machado
15:00
Oral presentation
3. Variation in the drugs involved in acute drug toxicity presentations based on age and sex within the Euro-DEN Plus dataset
15:00
to
16:30
Central square 2 (C2)
Òscar Miró
Oral presentation
4. Deaths among acute drug toxicity presentations to the Euro-DEN Plus Network, 2014-2020
15:00
to
16:30
Central square 2 (C2)
Isabelle Giraudon
Oral presentation
1. New Psychoactive Substance Presentations to the Euro-DEN Plus Network
15:00
to
16:30
Central square 2 (C2)
Benjamin Crulli
Oral presentation
2. The clinical impact of ethanol co-use in patients with acute drug toxicity involving the use of central nervous system depressant recreational drugs
15:00
to
16:30
Central square 2 (C2)
Eva-Carina Heier
Oral presentation
0. Insights into acute recreational drug and NPS toxicity: an update from the Euro DEN Plus Project: Introduction
15:00
to
16:30
Central square 2 (C2)
Paul Dargan
16:50
Oral presentation
1. Cannabis use disorder and the brain: What’s culture got to do with it?
16:50
to
18:20
Knowledge market 2 (K2)
Janna Cousijn
Oral presentation
2. Resting state functional connectivity of the dorsal attention network in cannabis use disorder: a fMRI study
16:50
to
18:20
Knowledge market 2 (K2)
Lisa-Marie Greenwood
Oral presentation
3. Brain reward function in young people with a dsm-5 diagnosis of Cannabis Use Disorder: a fMRI study
16:50
to
18:20
Knowledge market 2 (K2)
Valentina Lorenzetti
Oral presentation
4. Neural response to reward anticipation after acute exposure to cannabis with and without cannabidiol in adults and adolescents
16:50
to
18:20
Knowledge market 2 (K2)
Martine Skumlien
Oral presentation
5. Acute effects of four CBD:THC ratios on attentional bias to cannabis and food cues: a randomized, double-blind, crossover study
16:50
to
18:20
Knowledge market 2 (K2)
Dominic Oliver
Friday, 25 November
10:50
Oral presentation
Increased risk of non-fatal overdose associated with NPS-type [‘street’] benzodiazepine use in Scotland, UK
10:50
to
12:20
Knowledge market 3 (K3)
Andrew McAuley
Oral presentation
Variations in the protective association between opioid agonist therapy and opioid overdose death by age and chronic disease status: findings from the OATS retrospective linked data study, NSW, Australia, 2001-2018.
10:50
to
12:20
Knowledge market 3 (K3)
Sarah Larney
Oral presentation
Temporal trend in the survival of injecting and non-injecting heroin-dependent patients admitted to treatment in Barcelona, Spain: a 30-year cohort study.
10:50
to
12:20
Knowledge market 3 (K3)
Anna Hernández-Rubio
Oral presentation
The impact of opioid agonist treatment on fatal and non-fatal drug overdose among people with a history of opioid dependence in NSW, Australia, 2001-2018.
10:50
to
12:20
Knowledge market 3 (K3)
Nicola Jones
Oral presentation
Size Matters: Comparing the MDMA content and weight of ecstasy tablets submitted to European drug checking services in 2012-2021
10:50
to
12:20
Central square 3 (C3)
Ruben Vrolijk
Oral presentation
Shifting stages of ATS use and evidence-based intervention for risk reduction
10:50
to
12:20
Central square 3 (C3)
Nienke Liebregts
Oral presentation
Polydrug use typologies of regular ecstasy users visiting electronic dance music events in the United Kingdom and the Netherlands: A Latent Class Analysis.
10:50
to
12:20
Central square 3 (C3)
Ruben Van Beek
Oral presentation
Drug use and harm reduction in techno parties: some lessons learned from 20 years of fieldwork
10:50
to
12:20
Central square 3 (C3)
Fabrice Guilbaud
Oral presentation
New psychoactive substances tested by Energy Control, a community-based service of drug-checking and harm-reduction in Spain
10:50
to
12:20
Central square 3 (C3)
Adrià Quesada
13:20
e-poster
Functional Connectivity in a Triple-Network Saliency Model is Associated with Real-Life Self-Control
13:20
to
14:50
Networking zone 1 (N1)
Klaus-Martin Krönke
e-poster
Lifestyle risk factors and racial and ethnic inequality in mortality: Decomposing differential exposure and vulnerability in the United States
13:20
to
14:50
Networking zone 1 (N1)
Klajdi Puka
e-poster
Demographic and socio-structural factors associated with non-fatal overdose among patients enrolled in the OPTIMA trial
13:20
to
14:50
Networking zone 1 (N1)
Hannah Crepeault
e-poster
Acceptance-based, intersectional stigma coping intervention for people with HIV who inject drugs – an RCT in St. Petersburg, Russia
13:20
to
14:50
Networking zone 1 (N1)
Karsten Lunze
e-poster
Novel Psychoactive Substances (NPS) related health responses implemented in Europe through the lens of an intersectional risk environment approach
13:20
to
14:50
Networking zone 1 (N1)
Jessica Neicun
e-poster
Alcohol Consumption during a Pandemic Lockdown Period and Change in Alcohol Consumption Related to Worries and Pandemic Measures
13:20
to
14:50
Networking zone 1 (N1)
Silvia Eiken Alpers
e-poster
Gender differences in HIV prevalence and all-cause mortality among people who inject drugs (PWID) in Estonia.
13:20
to
14:50
Networking zone 1 (N1)
Maris Salekesin
e-poster
Interaction between Alcohol Use Disorder, APOE4 and Cognitive Decline in patients undergoing an alcohol detoxification program
13:20
to
14:50
Networking zone 1 (N1)
Laura Orio